News leaked that a federal task force has reversed its preliminary position on Exact Sciences’ colon cancer test causing the company’s stock to trade much higher than it had in previous months. The earlier position last year caused a severe drop in the Madison company’s stock price. Cologuard will now be viewed on the same level as other colorectal screen tests and no longer as an “alternative.” In a column, which appeared back in October of 2015, Tom Still took the long view and expected the decision to be reversed and the stock to rebound. See below for news coverage on Exact Sciences.

WisBusiness: Exact Sciences’ Conroy praises ‘great news’ as federal panel reverses position Exact Sciences stock rides roller coaster after Cologuard cancer test gets boost

Biz Journal: Exact Sciences shares surge on leak of test recommendations